Colgate-Palmolive (NYSE:CL) Stock Rating Lowered by StockNews.com

Colgate-Palmolive (NYSE:CL) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

A number of other analysts also recently weighed in on the company. TD Cowen dropped their target price on Colgate-Palmolive from $115.00 to $110.00 and set a “buy” rating for the company in a research report on Monday. Jefferies Financial Group cut Colgate-Palmolive from a “buy” rating to a “hold” rating and decreased their price target for the stock from $103.00 to $95.00 in a research note on Wednesday, July 24th. UBS Group lifted their price target on Colgate-Palmolive from $119.00 to $122.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Barclays lifted their price target on Colgate-Palmolive from $91.00 to $96.00 and gave the stock an “equal weight” rating in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. lifted their price target on Colgate-Palmolive from $113.00 to $114.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $105.11.

Colgate-Palmolive Price Performance

NYSE:CL traded down $0.99 during mid-day trading on Tuesday, reaching $94.75. The stock had a trading volume of 5,414,973 shares, compared to its average volume of 4,356,175. The firm has a 50 day moving average price of $102.86 and a two-hundred day moving average price of $98.19. The stock has a market capitalization of $77.74 billion, a P/E ratio of 29.98, a P/E/G ratio of 3.54 and a beta of 0.40. Colgate-Palmolive has a one year low of $72.36 and a one year high of $109.30. The company has a debt-to-equity ratio of 16.90, a quick ratio of 0.70 and a current ratio of 1.06.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, July 26th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.04. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $5 billion. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. Colgate-Palmolive’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.77 EPS. As a group, analysts expect that Colgate-Palmolive will post 3.57 earnings per share for the current year.

Insiders Place Their Bets

In other Colgate-Palmolive news, Director Martina Hundmejean sold 2,313 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total value of $240,228.18. Following the sale, the director now directly owns 11,755 shares of the company’s stock, valued at approximately $1,220,874.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Panagiotis Tsourapas sold 14,794 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $102.94, for a total transaction of $1,522,894.36. Following the transaction, the insider now directly owns 5,146 shares of the company’s stock, valued at $529,729.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Martina Hundmejean sold 2,313 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $103.86, for a total value of $240,228.18. Following the transaction, the director now directly owns 11,755 shares in the company, valued at approximately $1,220,874.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,490 shares of company stock valued at $4,486,063. 0.34% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. E Fund Management Hong Kong Co. Ltd. purchased a new stake in Colgate-Palmolive during the second quarter valued at $25,000. Continuum Advisory LLC increased its position in Colgate-Palmolive by 46.5% during the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after acquiring an additional 125 shares during the last quarter. Reston Wealth Management LLC purchased a new stake in Colgate-Palmolive during the third quarter valued at $42,000. Gradient Investments LLC increased its position in Colgate-Palmolive by 150.4% during the second quarter. Gradient Investments LLC now owns 666 shares of the company’s stock valued at $65,000 after acquiring an additional 400 shares during the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in Colgate-Palmolive during the second quarter valued at $68,000. 80.41% of the stock is owned by institutional investors.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.